(Bloomberg) There’s high-conviction funds, and then there’s Stephen Diggle’s health-care funds. The hedge fund veteran’s $100 million Vulpes Life Sciences Class A fund holds only two stocks, and the $50 million Class B fund just three. While the strategy has paid off — the Class A fund has returned 80 percent this year through May 25 after almost tripling last year — Diggle says it’s time to diversify and is opening the funds to outside investors as he targets as many as 12 listed and privately held biotech investments.
This Fund Returned 80% for Investors, With Just Two Stocks
This entry was posted in Syndicated. Bookmark the permalink.
